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Abstract
Background
International melioidosis treatment guidelines recommend a minimum 10 to 14 days’ intra-
venous antibiotic therapy (intensive phase), followed by 3 to 6 months’ oral therapy (eradi-
cation phase). This approach is associated with rates of relapse, defined as recurrence
following the eradication phase, that can exceed 5%. Rates of recrudescence, defined as
recurrence during the eradication phase, have not previously been reported. In response to
low eradication phase completion rates in Australia, a local guideline has evolved over the
last ten years recommending a longer minimum intensive phase duration for many cases
of melioidosis.
Methodology/ Principal Findings
This retrospective cohort study reviews antibiotic duration for the first episode of care for all
patients diagnosed with melioidosis and surviving the intensive phase during a recent three
year period in the tropical north of Australia’s Northern Territory; we also review adherence
to the current local guideline and treatment outcomes. Of 215 first episodes of melioidosis
surviving the intensive phase, the median (interquartile range) intensive phase duration
was 26 (14-34) days. One hundred and eight (50.2%) patients completed eradication thera-
py; 58 (27.0%) patients took no eradication therapy. At 28 months’ follow-up, one (0.5%) re-
lapse and eleven (5.1%) recrudescences had occurred. On exact logistic regression
analysis, the only independent risk factors for recrudescence were self-discharge during
the intensive phase (odds ratio 6.2 [95% confidence interval 1.2-30.0]) and septic shock
(odds ratio 5.3 [95% confidence interval 1.1-25.7]).
Conclusions/ Significance
Relapsed melioidosis is rare in patients who receive a minimum intensive phase duration
specified by our guideline and extended according to clinical progress. Recrudescence
rates may improve with reductions in rates of self-discharge. Given the low relapse rate
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despite a high rate of eradication therapy non-adherence, the duration and necessity of
eradication therapy for different patients after guideline-concordant intensive therapy
should be evaluated further.
Author Summary
Melioidosis is an infection caused by the soil bacterium Burkholderia pseudomallei; pa-
tients usually present with pneumonia, blood-stream infection and/or skin or internal
organ abscesses. Melioidosis occurs most commonly in northern Australia and parts of
Southeast Asia. It has a high mortality rate and, with standard treatment, a relapse rate
greater than 5%; patients who relapse often represent severely unwell. Treatment com-
prises an intensive (intravenous antibiotic) phase, followed by a prolonged eradication
(oral antibiotic) phase. Previous studies have found that the intensive phase is important
to prevent mortality, and the eradication phase is important to prevent relapse. However,
these studies have not been designed to detect an effect of intensive therapy on relapse
rate. We know that adherence to eradication therapy is poor, and many of our patients live
remotely making follow-up difficult. In order to address this, we have developed a new
treatment guideline which stipulates a longer intensive phase for most patients. We show
that adherence to this guideline is associated with very low relapse rates despite poor ad-
herence to eradication therapy. It is possible that for many patients the eradication phase
could be shortened or avoided when this intensive phase guideline is followed; this re-
quires further research.
Introduction
Burkholderia pseudomallei, the cause of melioidosis, is a soil- and water-borne bacterium en-
demic to northern Australia and parts of south-east Asia [1]. It most commonly causes pneu-
monia, bacteremia without evident focus, deep-seated abscesses and skin infection but can
affect almost any part of the body [2]. It causes more serious disease in patients with impaired
innate immunity such as those with diabetes and has a high mortality rate ranging from 9% to
49% [3–5]. It is intrinsically resistant to most antibiotics and requires prolonged therapy for
cure [5–8].
Current international guidelines suggest treatment with a minimum 10 to 14 days’ intrave-
nous antibiotics (intensive phase) followed by 3 to 6 months’ oral antibiotics (eradication
phase) [1,9,10]. Options for the intensive phase include ceftazidime or a carbapenem [10–13];
options for the eradication phase include trimethoprim-sulfamethoxazole (TMP-SMX), doxy-
cycline or amoxicillin-clavulanate [10,14–19]. Whilst there is provision in these international
guidelines to extend the intensive phase to four weeks or greater in severe cases of melioidosis,
the focus of the international guidelines is on switching to the eradication phase once the pa-
tient has been afebrile for 48 hours with negative blood cultures and an ability to take medica-
tion orally [9,10,17].
Despite treatment according to such guidelines, patients still have a high rate of relapse. In
the Northern Territory (NT) of Australia, from 1989 to 2009, 5.2% of 465 patients surviving
the intensive phase have had molecularly confirmed relapse [4,20]. In Thailand, rates of relapse
between 1986 and 2004 were at least 9.3% [5]. More recent data from a Thai randomized con-
trolled trial demonstrated a relapse rate of somewhere between 1.1% and 6.4% [17]. Choice
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and duration of oral eradication therapy have been found to be the strongest risk factors for re-
lapse [5].
A substantial proportion of our patients fail to complete the eradication phase and many
live in remote communities making follow up difficult. In response to this, intensive phase
therapy in our region has been progressively lengthened over the last 10 years. This is reflected
in a local guideline developed at Royal Darwin Hospital (RDH) directing duration of therapy
according to site of infection which in many cases extends intensive therapy far beyond defer-
vescence with negative blood cultures and an ability to take oral antibiotics. In this study, we re-
view antibiotic duration received by patients with melioidosis over a recent three year period,
clinician and patient adherence to the local guideline and associated outcomes.
Methods
Design
This study was a retrospective analysis of data from the ongoing Darwin Prospective Melioido-
sis Study [4,21], a prospective cohort study. The study size was determined by the number of
patients diagnosed with melioidosis during a recent period in and since which the guideline
being evaluated has remained substantially unchanged.
Patients
All patients with culture-confirmed melioidosis in the tropical Top End of the NT diagnosed
between 1st October 2009 and 30th September 2012 who survived the intensive phase were eli-
gible for inclusion in the study. Antibiotic therapy was managed by the Infectious Diseases De-
partment at RDH. Exclusion criteria included cases that represented recrudescence or relapse
of melioidosis first diagnosed prior to 1st October 2009 and cases with incomplete or inaccessi-
ble records. Antibiotic type and duration were reviewed for both the intensive and eradication
phases along with demographic, clinical and laboratory data; these data had been recorded pro-
spectively as part of the ongoing Darwin Prospective Melioidosis Study [4,21].
Definitions
Intensive phase was defined as the period of time during which the patient received intravenous
therapy directed against B. pseudomallei irrespective of clinician-intended duration. Eradication
phase was defined as the period of time commencing at the end of the intensive phase and fin-
ishing at the guideline-recommended end date of eradication therapy irrespective of actual dura-
tion received. Intensive and eradication therapy referred to the intravenous and oral antibiotics
directed against B. pseudomallei during the intensive and eradication phase respectively.
Recrudescence and recurrence were defined as return of clinical illness during and after the
eradication phase respectively with concomitant culture of B. pseudomallei from a clinical spec-
imen. Recurrence was further defined as either relapse or reinfection when isolates from the
initial and subsequent illness were identical or different respectively by multilocus sequence
typing (MLST) [20]. Cure was defined as the absence of death during the eradication phase or
recrudescence or relapse at the end of the follow-up period.
Risk factors were defined as in the Darwin Prospective Melioidosis Study [4]. Antibiotic du-
ration-determining focus (ADDF) was the focus requiring the longest minimum intensive
phase duration according to the local guideline; if there were two or more such foci requiring
the same minimum intensive phase duration, the ADDF was whichever of these appeared low-
est on Table 1, this being the focus generally considered most difficult to cure. Self-discharge
was defined as voluntary cessation of inpatient status prior to completion of the clinician-
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planned intensive phase irrespective of guideline minimum duration. Non-adherence to eradi-
cation therapy was defined as cessation of eradication therapy prior to recrudescence or, if pa-
tients did not recrudesce, prior to the end of the eradication phase.
Guideline
The Darwin Melioidosis Guideline is summarized in Table 1. First line intensive therapy was
ceftazidime unless the patient was in the intensive care unit (ICU) or allergic or intolerant to
ceftazidime in which case meropenem was used. If there were a collection (including skin ab-
scess or septic arthritis), bone or central nervous system (CNS) involvement, TMP-SMX, doxy-
cycline or amoxicillin-clavulanate (in order of preference) was added early during the intensive
phase for tissue penetration, usually orally. Subsequent oral eradication therapy used the same
choice of these latter three antibiotics. Eradication phase was 90 days for each ADDF except
osteomyelitis, CNS infection and arterial infection when 180 days was used. As noted in
Table 1, there was a small change to the guideline on 1st October 2010; clinician adherence was
assessed against the final version of the guideline.
Follow-up
Patients who survived the intensive phase were generally reviewed at monthly infectious dis-
eases outpatient visits until completion of eradication therapy. Where patients failed to attend
appointments, eradication therapy was assumed to have ceased at the last infectious diseases
appointment attended or the last of any subsequent entries documenting therapy in the RDH
medical record or NT-wide shared electronic health record. Follow-up data until 1st December
2014 were included; follow-up between the last clinic appointment and 1st December 2014 was
performed retrospectively by reviewing hospital and community shared electronic health rec-
ords. Melioidosis is a notifiable disease in the NT; data on melioidosis recurrence were based
on Australia-wide laboratory notification of positive cultures to the NT public health unit.
Table 1. Darwin melioidosis guideline.
Antibiotic Duration-Determining Focus Minimum intensive phase duration (weeks)a Eradication phase duration (days)
Skin abscess 2 90
Bacteremia with no focus 2 90
Pneumonia without lymphadenopathyb or ICU admission 2 90
with either lymphadenopathyb or ICU admission 4 90
Deep-seated collectionc 4d 90
Osteomyelitis 6 180
Central nervous system infection 8 180
Arterial infectione 8d 180
a. Clinical judgement to guide prolongation of intensive phase if improvement is slow or if blood cultures remain positive at 7 days.
b. Deﬁned as enlargement of any hilar or mediastinal lymph node to greater than 10mm diameter.
c. Deﬁned as abscess anywhere other than skin, lungs, bone, CNS or vasculature; septic arthritis is considered a deep-seated collection.
d. Intensive phase duration is timed from date of most recent drainage or resection where culture of the drainage specimen or resected material grew B.
pseudomallei or where no specimen was sent for culture; clock is not reset if specimen is culture-negative. On 1st October 2010, the minimum duration for
deep-seated collection changed from 2 to 4 weeks from last such drainage/resection.
e. Most commonly presenting as mycotic aneurysm.
doi:10.1371/journal.pntd.0003586.t001
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Data analysis
Data not normally distributed were expressed as median ± interquartile range (IQR). Bivariate
analysis of categorical and continuous variables was performed using the two-tailed Fisher
exact test (due to low expected cell values) and the Wilcoxon rank-sum test respectively. Signif-
icant variables on bivariate analysis at p< 0.05 were assessed by multivariate analysis using
exact logistic regression; exact methods were used due to the infrequency of recrudescence.
Stepwise elimination of variables least significant on bivariate analysis was performed until all
variables remaining in the model were statistically significant. Analyses were performed using
Stata version 12 (StataCorp, College Station, TX).
Ethics
This study was approved by the Human Research Ethics Committee of the NT Department of
Health and the Menzies School of Health Research (HREC 02/38). As this was a retrospective
observational study of a large dataset of a notifiable disease and data were analyzed anony-
mously, consent was not required.
Results
Patients
Two hundred and fifty patients were diagnosed with melioidosis and managed by the RDH In-
fectious Diseases Department between 1st October 2009 and 30th September 2012. Twenty-
seven (10.8%) of these died during the intensive phase, one was a relapse of a case diagnosed
prior to 1st October 2009 and a further seven had incomplete antibiotic data due to missing
files or partially interstate treatment; these patients were excluded leaving 215 patients in the
study. All 215 patients were followed up as outlined in the methods and data analysis was per-
formed on all patients except where stated.
Baseline characteristics are shown in Table 2. The median (IQR) age was 49.6 (39.0–60.5)
years; 119 (55.3%) patients were male and 15 (7.0%) were under 18 years of age. The cohort
had a high rate of comorbidity with 181 (84.2%) patients having at least one recognized risk
factor for melioidosis. In addition, melioidosis was of characteristic severity with 128 (59.5%)
patients bacteremic, 47 (21.9%) requiring intensive care and 32 (14.9%) developing
septic shock.
Treatment
Intensive therapy duration is shown in Table 3. The median (IQR) intensive phase duration for
the 215 patients overall was 26 (14–34) days. Twenty (9.3%) patients self-discharged during
the intensive phase. Of 133 (61.9%) patients who completed their intravenous therapy through
the RDH Hospital in the Home program, the median (IQR) duration of infusor therapy was 14
(8–22) days.
Median intensive phase duration according to ADDF is shown in Fig. 1. When self-dis-
chargers were excluded, patients with bacteremia with no focus or osteomyelitis as an ADDF
tended to have a longer intensive phase duration than the guideline minimum duration. For
patients with bacteremia with no focus, the most common reasons for prolonged therapy were
immunosuppression (1 on cancer chemotherapy, 1 on high dose dexamethasone for cerebral
metastases and 1 with systemic lupus erythematosus-related neutropenia) and, in hindsight, in-
correctly suspected other foci of infection (3 patients). Patients with osteomyelitis were more
likely to have multifocal disease as depicted in Fig. 2 and tended to be slower to improve result-
ing in an extension of the intensive phase.
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Eradication phase duration was bimodal with one peak occurring at 90 days (93 [43.3%] pa-
tients) and a second peak at 0 days (58 [27.0%] patients). Only 108 (50.2%) patients completed
the guideline-specified eradication phase. In total, 70.7% of eradication therapy days were with
TMP-SMX; 29.3% were with doxycycline. No patients received amoxicillin-clavulanate.
Clinician adherence to intensive phase duration
Adherence to the guideline-specified minimum intensive phase duration by clinicians accord-
ing to ADDF is demonstrated in Fig. 3; self-discharging patients are excluded as it was not pos-
sible for clinicians to adhere in these cases. Of the remaining 195 patients, 43 (22.1%) received
less than the guideline-directed minimum intensive phase duration. In most cases of clinician
non-adherence, the ADDF was skin abscess, pneumonia or deep-seated collection. Of the
Table 2. Baseline characteristics.
Baseline characteristic Number (%a) except where
indicated
Demographics Male 119 (55.3)
Age 49.6 (39.0–60.5)b
Risk factor Any risk 181 (84.2)
Diabetes 100 (46.5)
Hazardous alcohol use 86 (40.0)
Chronic lung disease 59 (27.4)
Chronic renal disease 27 (12.6)
Malignancy 26 (12.1)
Immunosuppression 26 (12.1)
Congestive cardiac failure / rheumatic heart
disease
21 (9.8)
Severity Bacteremia 128 (59.5)
ICU admission 47 (21.9)
Septic shock 32 (14.9)
Antibiotic duration-determining focusDeep-seated
collection
Skin abscess 26 (12.1)
Bacteremia no focus 14 (6.5)
Pneumonia 102 (47.4)
Deep-seated collection 56 (26.0)
Osteomyelitis 12 (5.6)
Central nervous system infection 4 (1.9)
Arterial infection 1 (0.5)
Deep-seated collection Prostate 23 (10.7)
Septic arthritis 13 (6.0)
Spleen 12 (5.6)
Liver 10 (4.7)
Deep soft tissue 9 (4.2)
Kidney 7 (3.3)
Muscle 6 (2.8)
Pericardial 3 (1.4)
Other 9 (4.2)
a. The denominator for all percentage calculations is 215; there were no missing values.
b. Median (interquartile range).
doi:10.1371/journal.pntd.0003586.t002
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pneumonia cases, most had minor degrees of hilar/mediastinal lymphadenopathy and did not
receive four weeks’ intensive therapy; of the deep-seated collection cases, most occurred in the
first year of the study when it was common for patients to receive two rather than four weeks’
intensive therapy from last drainage. Despite this, 42/43 (97.7%) clinician non-adherent cases
had cure of their infection.
Outcomes
Of the 215 patients, 197 (91.6%) patients were cured. The median (range) duration of follow-
up from the onset of the eradication phase for these cured patients was 45.9 (28.4–
61.1) months.
Six (2.8%) patients died during the eradication phase. All six were palliated with eradication
therapy ceased by the attending physicians prior to death. Five patients had incurable malig-
nancy and one had advanced dementia. Two of the six patients had fever before dying but were
not investigated due to their palliative status. A third patient, a 64 year old man with bacter-
emia with no focus, had been treated with four weeks’ ceftazidime followed by two weeks’ cotri-
moxazole; this was then ceased due to a rash and was not replaced due to his palliative status in
the context of squamous cell carcinoma of the lung with brain metastases, hypercalcemia and
delirium requiring dexamethasone. He died 27 days after cessation of cotrimoxazole. Three
days prior to dying he had a throat swab collected to investigate pneumonia; this grew B. pseu-
domallei 2 days after death. He was counted as a death during the eradication phase rather
Table 3. Duration of intensive therapy.
Antibiotic Patients No. of patients Duration (days)
Median Interquartile range
Meropenem and ceftazidime Total Total 215 26 14–34
Non-self-dischargers 195 27 14–35
Self-dischargers 20 17 13–25.5
From last drainage Total 215 25 14–30
Non-self-dischargers 195 27 14–31
Self-dischargers 20 17 12.75–25.5
Meropenema Total Total 97 7 3–18
Non-self-dischargers 86 7 3–18
Self-dischargers 11 5 3.5–16
From last drainage Total 97 6 2–16
Non-self-dischargers 86 6 2–16
Self-dischargers 11 5 3–16
Ceftazidimeb Total Total 204 18.5 14–28.25
Non-self-dischargers 185 19 14–29
Self-dischargers 19 13 10.5–22
From last drainage Total 204 17 14–28
Non-self-dischargers 185 18 14–28
Self-dischargers 19 13 10.5–22
a. Excludes 118 patients who did not receive any meropenem.
b. Excludes 11 patients who did not receive any ceftazidime.
doi:10.1371/journal.pntd.0003586.t003
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than a recrudescence as he was being actively palliated. The remainder of the six patients had
no clinical evidence of infection prior to death.
Eleven (5.1%) patients recrudesced after their initial admission. The median (IQR) time to
recrudescence from the end of the intensive phase was 24 (13–43) days; the median (IQR) time
from the last day of taking eradication therapy was 10 (0–22) days with four (36%) patients still
taking their eradication therapy when they recrudesced. Of these four, three had an appropriate
intensive phase duration according to the guideline but two of these recrudesced with infected
foreign bodies that had not initially been evident clinically (staghorn calculus and suspected
vascular graft infection) and the third had bronchiectasis with persistent sputum positivity.
Only one (0.5%) relapse occurred. This was a 34 year old man with pneumonia, mediastinal
lymphadenopathy and an undrained liver abscess who self-discharged after 15 days’ intensive
therapy and took no eradication therapy. He relapsed 15 months later with severe sepsis due to
worsening pulmonary abscesses and mediastinal lymphadenopathy but had a stable-appearing
liver abscess.
One (0.5%) patient had reinfection. He was considered for the purpose of analysis to have
had cure of his original infection.
There were no patients with clinically-suspected but culture-unproven recrudescence
or recurrence.
Fig 1. Median treatment duration from last drainage ± interquartile range in comparison to minimum guideline duration.
doi:10.1371/journal.pntd.0003586.g001
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Bivariate analysis was performed to assess for significant predictors of recrudescence. Pa-
tients who died during the eradication phase were excluded due to a shorter exposure to the
possibility of recrudescence and a likely bias toward not diagnosing recrudescence due to the
palliative nature of these patients. This left 209 patients in the analysis. Results of analysis of
categorical variables are shown in Table 4. The median (IQR) age for patients who did and did
not recrudesce was 46.3 (41.2 to 55.6) and 49.6 (38.8–59.9) years respectively (p = 0.47). The
only variables significantly predicting recrudescence were diabetes, having osteomyelitis as an
ADDF, admission to ICU, septic shock and self-discharge. Multivariate analysis showed that
only two of these variables were statistically significant independent predictors of recrudes-
cence; these were self-discharge (odds ratio 6.2 [95% confidence interval 1.2–30.0, p< 0.05])
and septic shock (odds ratio 5.3 [95% confidence interval 1.1–25.7, p< 0.05]).
A subgroup analysis was performed on the 58 patients who took no eradication therapy; 52
(89.7%) were cured, 2 (3.4%) died during the eradication phase, 3 (5.2%) recrudesced and 1
(1.7%) relapsed.
Discussion
The evolving therapy of melioidosis over the last 25 years has largely been informed by sequen-
tial randomized controlled trials from Thailand [11,13–17,22–27]. All trials assessing intensive
phase therapy in melioidosis have had mortality as a primary endpoint; none has included re-
lapse as an endpoint [11,13,22,23,25–27]. Minimum duration of intensive therapy in these
studies has been 7–14 days with a median of 7–15 days’ therapy actually administered. No
Fig 2. Median number of foci of infection ± interquartile range according to antibiotic duration-determining focus.
doi:10.1371/journal.pntd.0003586.g002
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study has randomized patients to different intensive phase durations. All randomized con-
trolled trials assessing eradication therapy have had relapse as a primary endpoint [14–17,24];
these studies have repeatedly found that eradication therapy choice, duration and compliance
affect relapse rate whereas intensive phase choice and duration do not.
Based on these studies, current international guidelines recommend a minimum of 10 days’
intravenous therapy for melioidosis [1,9]. However, patients treated according to these guide-
lines still have a high relapse rate. In the most comprehensive retrospective study of relapse [5],
isolates were analyzed for all 921 patients diagnosed from 1986 to 2004 in northeast Thailand
who survived the intensive phase and presented for follow-up; 9.3% of patients had a proven
relapse although a further 3.5% did not have paired isolates available for testing [5]. Not all pa-
tients in this study had been treated according to current guidelines as many had been part of
randomized controlled trials evaluating experimental treatment regimens; indeed, only in 1994
was the minimum intensive phase duration switched from 7 to 10 days. Nonetheless, choice
and duration of eradication therapy were the strongest predictors of relapse; other risk factors
included bacteremia and multifocal disease. Choice and duration of intravenous therapy were
found not to be risk factors for relapse [5].
This Thai study defined relapse as new symptoms and signs of infection plus B. pseudomal-
lei culture positivity after an initial response to therapy [5], similar to a combination of our def-
initions for recrudescence and relapse. Given that the median (IQR) time to proven relapse in
the Thai study was 26 (10–72) weeks and 62% of patients had more than 16 weeks’ eradication
therapy [5], it is likely that a proportion of such relapses were actually recrudescences accord-
ing to our definition.
Fig 3. Clinician adherence to guideline-specifiedminimum intensive phase duration excluding patients who self-discharged.
doi:10.1371/journal.pntd.0003586.g003
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In a recent Thai randomized controlled trial [17], which followed the current international
guidelines, the rate of culture-confirmed melioidosis recurrence was 5.9% but it was not possi-
ble to determine what proportion of these were recrudescences, relapses or reinfections accord-
ing to our definition. Based on the data provided, the maximum possible range for the relapse
rate was 1.1–6.4%; this range includes patients with clinically suspected but culture-unproven
relapse (maximum 2.9%). Inclusion criteria for this trial included satisfactory completion of in-
tensive therapy and a high likelihood of completing at least six months’ follow-up; thus this re-
lapse rate may not be externally valid for the general population.
The relapse rate in the NT from 1989 to 2009, defined as recurrence with the same MLST
occurring after the end of the eradication phase, was 5.2% [4,20]. This rate has decreased over
the last decade in parallel with a progressive lengthening of the intensive phase to compensate
for poor eradication therapy adherence [20]. The current guideline is associated with a median
26 day intensive phase duration. That only 1/215 (0.5%) patients relapsed and yet only 50.2%
Table 4. Bivariate analysis of categorical risk factors for recrudescence.
Risk factor Number
(%a)
Odds ratio (95% conﬁdence
interval)
P
value
Demographics Male 115 (55.0) 0.98 (0.24–4.20) 1.000
Risk factor Any risk 175 (83.7) undeﬁned 0.218
Diabetes 97 (46.4) 5.63 (1.12–54.41)* 0.026
Hazardous alcohol use 86 (41.1) 1.20 (0.28–4.91) 0.763
Chronic lung disease 56 (26.8) 1.60 (0.33–6.60) 0.490
Chronic renal disease 26 (12.4) 0.69 (0.02–5.26) 1.000
Immunosuppression 23 (11.0) 0.00 (0.00–2.74) 0.615
Malignancy 21 (10.0) 0.89 (0.02–6.88) 1.000
Congestive cardiac failure / rheumatic heart disease 21 (10.0) 0.00 (0.00–3.05) 0.607
Severity Bacteremia 122 (58.4) 1.96 (0.45–11.80) 0.367
ICU admission 47 (22.5) 6.91 (1.64–33.40)** 0.003
Septic shock 31 (14.8) 8.30 (1.92–36.55)** 0.002
ADDF Skin abscess 26 (12.4) 0.00 (0.00–2.38) 0.366
Bacteremia no focus 13 (6.2) 0.00 (0.00–5.22) 1.000
Pneumonia 99 (47.4) 0.62 (0.13–2.53) 0.544
Deep-seated collection 54 (25.8) 1.08 (0.18–4.72) 1.000
Osteomyelitis 12 (5.7) 7.88 (1.13–40.2)* 0.019
Central nervous system infection 4 (1.9) 0.00 (0.00–18.46) 1.000
Adequacy of
treatment
Self-discharge 20 (9.6) 10.17 (2.14–44.52)** 0.002
 2 weeks intensive phase 61 (29.2) 0.52 (0.05–2.65) 0.515
Less than minimum intensive phase per guideline 81 (38.8) 2.93 (0.71–14.06) 0.112
Non-adherence to eradication therapy 97 (46.4) 2.10 (0.51–10.07) 0.353
Doxycycline vs cotrimoxazole as predominant eradication therapy 41 (26.8)b 2.92 (0.512–16.38) 0.211
No eradication therapy vs cotrimoxazole as predominant
eradication therapy
56 (33.3)c 1.53 (0.216–9.36) 0.687
a. The denominator for all percentage calculations is 209 except where stated; there were no missing values.
b. Numerator and denominator for percentage calculation represent number of patients with doxycycline and either doxycycline or cotrimoxazole as the
predominant eradication therapy respectively.
c. Numerator and denominator for percentage calculation represent number of patients with no eradication therapy and either no eradication therapy or
cotrimoxazole as the predominant eradication therapy respectively.
doi:10.1371/journal.pntd.0003586.t004
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of patients completed the eradication phase suggests that the longer duration of the intensive
phase is important in preventing relapse. It is possible that further relapses could occur after
the follow-up period but, considering that our shortest follow-up duration, 28.4 months, well
exceeds the median time to relapse in the NT, 8 months [4], most relapses would be expected
to occur within the follow-up period.
That 42 of 43 (97.7%) cases where clinicians were not adherent to the local guideline were
cured suggests that the guideline can be further refined. For instance, it is common in the NT
to give only two or three days’ intensive therapy for skin abscesses pending exclusion of other
foci on culture and imaging and it may be that no intensive therapy is necessary if adherence to
oral therapy is likely in these patients. Oral therapy alone in some cases of skin abscess has
been successful in Australia [28,29], Thailand [30] and Cambodia [31] but careful exclusion of
other foci of infection and a high likelihood of oral therapy adherence are necessary if initial in-
travenous therapy is to be omitted. The importance of extending intensive therapy for pneu-
monia to four weeks for minor degrees of mediastinal or hilar lymphadenopathy is unclear;
however, in many countries where melioidosis occurs, x-rays are the only form of chest imag-
ing available and these will only detect gross lymphadenopathy. While lymphadenopathy may
reflect inhalational melioidosis and therefore potential for more severe disease [32], concerns
about radiation dose with computed tomography (CT) scanning caution against routine CT
imaging of the chest [33]. CT scans of the chest were not performed routinely in our study;
however, our analysis did include patients whose lymphadenopathy was only detected on CT
chest. In the case of deep-seated collection, it may be appropriate to refine the current guideline
to a minimum two weeks’ intensive therapy from last culture-positive drainage provided there
is a minimum of four weeks’ intensive therapy in total.
Whilst the recrudescence rate was higher than desired at 5.1%, there are no previous data,
including from our region, on strictly-defined recrudescence with which to compare our cur-
rent data; recrudescence in the Darwin Prospective Melioidosis Study has traditionally been
considered as part of the primary episode of infection while in the Thai studies it has some-
times been included in the relapse data. Of note, the 5.2% historical relapse rate from our re-
gion [4] used the same definition of relapse reported here and therefore did not include any
recrudescences; when recrudescences occurred, they were considered part of the primary epi-
sode of infection. That recrudescences occurred in the current study supports that our guide-
line minimum intensive phase durations were overall not too long.
Many of the cases of recrudescence were explainable. That self-discharge was a significant
independent risk factor for recrudescence suggests that if fewer patients had self-discharged we
would likely have observed a lower recrudescence rate. Ongoing efforts are required to engage
these often highly vulnerable patients in inpatient care. Septic shock as an independent risk fac-
tor may reflect a higher initial bacterial burden and degree of immune suppression and thus a
requirement for a longer intensive phase to eradicate infection. This underscores the impor-
tance of extension of intensive therapy beyond the guideline minimum duration if clinical im-
provement is slow. As noted, there were two additional observed causes for recrudescence in
this study which were not tested in the analysis due to inadequate numbers, these being in-
fected foreign body (two patients) [5,34,35] and bronchiectasis (one patient) [36–38].
Whilst there was a correlation between self-discharge and eradication therapy non-adher-
ence, in that all 20 patients who self-discharged were non-adherent, these patients accounted
for only 20.6% of the 97 patients who were non-adherent. This explains the difference in out-
come on bivariate analysis for these two variables.
The discrepancy between our finding that eradication therapy adherence was not important
in predicting recrudescence or relapse and the Thai finding that choice and duration of eradica-
tion therapy were the most important predictors of relapse [5] may reflect that most of our
Melioidosis Intravenous Therapy Duration
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003586 March 26, 2015 12 / 16
patients were already cured by the longer intensive phase whereas the Thai patients were more
dependent on the eradication phase after a generally shorter intensive phase. The lack of a sig-
nificant effect of duration of intensive phase on relapse rate in the Thai studies may reflect in-
adequate diversity in intensive phase duration to detect such an effect [5,15].
The strengths of our study are the number of patients included and that most data were col-
lected prospectively. One limitation is that much follow-up data was collected retrospectively.
However, the NT has a robust shared electronic health record facilitated by an NT-wide unique
patient identification number allowing confirmation of outcome. Additionally, as melioidosis
is a notifiable disease in the NT, all Australian laboratories are mandated to report positive cul-
tures of NT patients to the NT public health unit which liaises with the RDH Infectious Dis-
eases Department. We acknowledge that there remains a theoretical possibility that patients
with recrudescent or recurrent melioidosis diagnosed after migration overseas may have
been missed.
Another limitation is that results are compared with historical findings [4] and attribution
of improvement in relapse rate to the guideline may be confounded by other interventions.
Furthermore, as the guideline evolved over a ten year period, it was not possible to use histori-
cal controls from a short period immediately preceding the period studied. Nonetheless, we are
not aware of any other changes in management which may have confounded outcomes. There
is biological plausibility in attributing lower relapse rates to the guideline in that intensive ther-
apy uses potent bactericidal antibiotics whereas eradication therapy uses bacteriostatic antibi-
otics. There has been a significant improvement in the melioidosis mortality rate over the last
twenty years in our region, attributed largely to improved intensive care [4], which has meant
that more patients with septic shock are surviving; these patients are at higher risk of recrudes-
cence and relapse [5] and yet they are not relapsing. Based on the above data and decades of
clinical experience, we do not believe that there is equipoise in our region for a randomized
controlled trial comparing traditional two weeks’ intensive therapy with our guideline mini-
mum intensive phase duration.
Our findings have important implications for management of melioidosis globally. Relapse
rates with traditional approaches to melioidosis therapy are high and present a significant risk
to patients and a burden on healthcare resources. Adoption of our guidelines may significantly
reduce relapse rates; however, many hospitals in Southeast Asia do not have Hospital in the
Home programs to facilitate domiciliary intravenous antibiotic administration and the cost of
intravenous ceftazidime itself is often prohibitive. Thus, significant improvements in funding
and resources may be required before our guideline can be adopted in these settings. Given the
near-zero relapse rate in our study, despite poor adherence to eradication therapy, further re-
search is required to evaluate eradication phase duration and necessity for different ADDFs fol-
lowing guideline-concordant therapy. If abbreviating or ceasing therapy after the intensive
phase were associated with no excess relapses, this would significantly shorten and improve tol-
erability and safety of the overall treatment regimen and obviate the need for long term follow
up, thus further improving the cost-benefit ratio of our approach.
Conclusions
We have developed a guideline for duration of intensive phase therapy for melioidosis that we
think is responsible for the very low rate of relapse now seen in the Top End of the NT. Its im-
mediate applicability in some developing regions is uncertain due to funding and resource is-
sues. However, given the excellent cure rates with our intensive phase guideline despite poor
adherence to subsequent eradication therapy, we believe that further research evaluating the
duration and necessity of the eradication phase for different ADDFs is now warranted.
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